Laser Photonics 8-K Delisting Notice

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

FORM 8-K

CURRENT
REPORT

Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date
of Report (Date of earliest event reported): April 20, 2026

LASER
PHOTONICS CORPORATION

(Exact
name of registrant as specified in its charter)

| Delaware | | 001-41515 | | 84-3628771 |
| (State of other jurisdiction | | (Commission | | (IRS Employer |
| of incorporation) | | File Number) | | Identification No.) |

| 250 Technology
Park |
| Lake Mary, FL | | 32746 |
| (Address of principal executive
offices) | | (Zip Code) |

Registrant’s
telephone number, including area code: (407) 804-1000

(Former
name or former address, if changed since last report.)

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):

| ☐ | Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |

| ☐ | Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |

| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |

| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |

| Title
of each class | | Trading
Symbol(s) | | Name
of each exchange on which registered |
| Common Stock | | LASE | | The Nasdaq Stock Market
LLC |

Emerging
growth company ☒

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On
April 20, 2026, the registrant (“Laser Photonics” or the “Company”) received a notice from Nasdaq Listing Qualifications
department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that since the Company has not yet filed its Form 10-K for the
year ended December 31, 2025, it no longer complies with Nasdaq’s Listing Rules (the “Rules”), specifically Listing
Rule 5250(c)(1), for continued listing. The notice from Nasdaq stated that the Company has 60 calendar days or until June 22, 2026, to
submit a plan to regain compliance, and if Nasdaq accepts the Company’s plan, Nasdaq can grant an exception of up to 180 calendar
days from the due date, or until October 12, 2026, to regain compliance by filing its Form 10-K for the year ended December 31, 2025
Any subsequent periodic filing that is due within the 180-day exception period must be filed no later than the end of the period.

Shortly
after the Company’s receipt of this notice from Nasdaq, the Company filed its Form 10-K for the year ended December 31, 2025, that
was delayed as a result of resolving accounting issues raised by the Company’s recently engaged independent registered public accounting
firm. Accordingly, on April 21, 2026, Nasdaq sent a letter to the Company stating that in light of the Company filing its Form 10-K
for the year ended December 31, 2025, that it now complied with Listing Rule 5250(c)(1) (the “Rule”) and that the matter
was now closed.

A
copy of the press release announcing this deficiency notice is attached hereto and incorporated herein to this Current Report on Form
8-K as Exhibit 99.1.

Item
9.01 Financial Statements and Exhibits.

Exhibits

| 99.1 | Press Release Issued by Laser Photonics Corporation dated April 22, 2026 |
| 104 | Cover Page Interactive Data File (embedded within the
Inline XBRL document) |

| - 2 - |

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.

| Date: April 21, 2026 | Laser Photonics
Corporation | |

| | By: | /s/ Wayne
Tupuola |
| Wayne Tupuola |
| President and CEO |

| - 3 - |